Rafferty Asset Management LLC Sells 19,442 Shares of Vericel Co. (NASDAQ:VCEL)

Rafferty Asset Management LLC reduced its position in shares of Vericel Co. (NASDAQ:VCELFree Report) by 15.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,814 shares of the biotechnology company’s stock after selling 19,442 shares during the period. Rafferty Asset Management LLC owned approximately 0.22% of Vericel worth $3,768,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale acquired a new position in shares of Vericel in the fourth quarter valued at about $33,000. GAMMA Investing LLC acquired a new stake in shares of Vericel in the fourth quarter valued at approximately $65,000. Sentry Investment Management LLC bought a new stake in shares of Vericel in the fourth quarter valued at approximately $136,000. PNC Financial Services Group Inc. grew its position in Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock worth $154,000 after buying an additional 344 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Vericel during the 4th quarter worth $197,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VCEL. Truist Financial reiterated a “buy” rating and set a $54.00 target price on shares of Vericel in a research report on Tuesday, March 26th. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, HC Wainwright raised their target price on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.80.

Read Our Latest Analysis on Vericel

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares in the company, valued at approximately $8,708,739.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now owns 195,307 shares in the company, valued at approximately $8,708,739.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Michael Halpin sold 7,874 shares of Vericel stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $44.71, for a total transaction of $352,046.54. Following the sale, the chief operating officer now owns 949 shares in the company, valued at $42,429.79. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,152 shares of company stock valued at $2,083,143. 5.20% of the stock is currently owned by insiders.

Vericel Stock Down 3.1 %

NASDAQ:VCEL opened at $44.38 on Friday. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The stock’s 50-day simple moving average is $47.98 and its 200 day simple moving average is $43.54. The firm has a market capitalization of $2.16 billion, a PE ratio of -4,433.57 and a beta of 1.74.

Vericel (NASDAQ:VCELGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The company had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.16) EPS. On average, analysts anticipate that Vericel Co. will post 0.09 EPS for the current fiscal year.

About Vericel

(Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.